← Leaderboards
Hideho Okada
University Of California, San Francisco
$20,052,698
Attributed
$20,919,125
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,919,125 · 18
By mechanism
R35$5,993,611 · 1
R01$5,123,148 · 3
R21$3,791,749 · 7
P01$3,465,213 · 4
U19$1,302,101 · 1
P50$1,240,250 · 1
Top collaborators
- Joseph F Costello2 shared
- Ian F. Pollack2 shared
- Edward G Shaw2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Satya Dandekar$23,346,836
- Arthur Weiss$25,258,536
- Robert M Stroud$50,842,733
- Trey Ideker$62,370,509
- Jeremy David Keenan$19,787,326
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGliomaAntigensImmunotherapyT-LymphocyteBaseCellsMalignant NeoplasmsBrain NeoplasmsSafetyChemokineSiteImmune ResponseMediatingHomingVaccinationClinical TrialsCytotoxic T-LymphocytesInterferonsGlioblastomaImmunotherapeutic AgentSignal TransductionPhenotypeOperative Surgical Procedures
Grant awards (65)
Preclinical development of breakthrough immunotherapy for brain tumors$783,609
R35 · FY2025 · NS · contact PI
Project 3: Novel B-SYNC T cell therapy with CNS-specific expression of CAR as a safe and effective therapy for glioblastoma$424,718
P50 · FY2025 · CA · contact PI
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma$258,407
U19 · FY2025 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$844,555
R35 · FY2024 · NS · contact PI
Project 3: Novel B-SYNC T cell therapy with CNS-specific expression of CAR as a safe and effective therapy for glioblastoma$409,599
P50 · FY2024 · CA · contact PI
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma$245,624
U19 · FY2024 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$725,326
R35 · FY2023 · NS · contact PI
Project 3: Novel B-SYNC T cell therapy with CNS-specific expression of CAR as a safe and effective therapy for glioblastoma$405,933
P50 · FY2023 · CA · contact PI
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma$253,519
U19 · FY2023 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$145,350
R35 · FY2023 · NS · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$725,326
R35 · FY2022 · NS · contact PI
Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression$362,043
R01 · FY2022 · CA · contact PI
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma$253,654
U19 · FY2022 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$725,326
R35 · FY2021 · NS · contact PI
Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression$369,431
R01 · FY2021 · CA · contact PI
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma$290,897
U19 · FY2021 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$722,707
R35 · FY2020 · NS · contact PI
Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression$369,431
R01 · FY2020 · CA · contact PI
Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade glioma$173,962
R21 · FY2020 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$719,525
R35 · FY2019 · NS · contact PI
Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression$356,129
R01 · FY2019 · CA · contact PI
Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade glioma$144,165
R21 · FY2019 · CA · contact PI
Preclinical development of breakthrough immunotherapy for brain tumors$601,887
R35 · FY2018 · NS · contact PI
Glioma immunotherapy targeting IDH mutation-derived epitope and immunosuppression$366,000
R01 · FY2018 · CA · contact PI
Novel K27M Mutation-derived Neoantigen for T Cell Therapy in Gliomas$346,719
R01 · FY2017 · NS · contact PI
Novel K27M Mutation-derived Neoantigen for T Cell Therapy in Gliomas$346,719
R01 · FY2016 · NS · contact PI
Antigens for Molecularly Targeted Vaccines for Progressive Glioma$237,750
R21 · FY2016 · NS · contact PI
Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cells$396,250
R21 · FY2015 · NS · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$346,263
R01 · FY2015 · NS · contact PI
Phase I Vaccine Study using Brain Tumor Initiating Cells in WHO Grade II Gliomas$202,051
R21 · FY2015 · CA · contact PI
Antigens for Molecularly Targeted Vaccines for Progressive Glioma$198,125
R21 · FY2015 · NS · contact PI
Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cells$395,208
R21 · FY2014 · NS · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$201,687
R01 · FY2014 · NS · contact PI
Phase I Vaccine Study using Brain Tumor Initiating Cells in WHO Grade II Gliomas$182,958
R21 · FY2014 · CA · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$119,910
R01 · FY2014 · NS · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$313,660
R01 · FY2013 · NS · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$205,460
P01 · FY2013 · CA · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$325,222
R01 · FY2012 · NS · contact PI
Molecularly targeted, multidisciplinary glioma vaccine approaches$245,353
P01 · FY2012 · NS · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$219,778
P01 · FY2012 · CA · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$22,848
P01 · FY2012 · CA · contact PI
Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells$325,402
R01 · FY2011 · NS · contact PI
Peptide-Based Vaccine Therapy for Childhood Malignant Gliomas$304,932
R21 · FY2011 · CA
Molecularly targeted, multidisciplinary glioma vaccine approaches$244,258
P01 · FY2011 · NS · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$220,235
P01 · FY2011 · CA · contact PI
A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma$332,564
R21 · FY2010 · CA · contact PI
Peptide-Based Vaccine Therapy for Childhood Malignant Gliomas$314,363
R21 · FY2010 · CA
Molecularly targeted, multidisciplinary glioma vaccine approaches$243,196
P01 · FY2010 · NS · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$238,036
P01 · FY2010 · CA · contact PI
A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma$345,121
R21 · FY2009 · CA · contact PI
Giloma Vaccines in Combination with Poly-ICLC$324,844
R01 · FY2009 · NS · contact PI
Type-1 Antigen Presenting Cells in CNS Tumors - Key to Efficient Anti-Tumor T-Cel$233,372
P01 · FY2009 · CA · contact PI
Molecularly targeted, multidisciplinary glioma vaccine approaches$187,247
P01 · FY2009 · NS · contact PI
DC-BASED CYTOKINE GENE IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS$178,183
P01 · FY2009 · CA · contact PI
Giloma Vaccines in Combination with Poly-ICLC$324,844
R01 · FY2008 · NS · contact PI
Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas$282,150
R21 · FY2008 · CA · contact PI
Molecularly targeted, multidisciplinary glioma vaccine approaches$243,754
P01 · FY2008 · NS · contact PI
DC-BASED CYTOKINE GENE IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS$192,214
P01 · FY2008 · CA · contact PI
Giloma Vaccines in Combination with Poly-ICLC$324,844
R01 · FY2007 · NS · contact PI
Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas$282,150
R21 · FY2007 · CA · contact PI
DC-BASED CYTOKINE GENE IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS$197,095
P01 · FY2007 · CA · contact PI
DC-BASED CYTOKINE GENE IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS$194,864
P01 · FY2006 · CA · contact PI
DC-BASED CYTOKINE GENE IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS$189,189
P01 · FY2005 · CA
Gene Therapy for Malignant Gliomas$3,053
M01 · FY2004 · RR
TUMOR VACCINE BASED IMMUNOTHERAPY OF MALIGNANT GLIOMAS$210,131
P01 · FY2002 · NS